Form 4: Royalty Pharma Executive Sells Shares in Planned Transactions

Royalty Pharma's EVP of Research & Investments, Marshall Urist, sold over 41,000 Class A Ordinary Shares in pre-arranged transactions.

Summary

• Marshall Urist, Executive Vice President of Research & Investments at Royalty Pharma plc, reported sales of Class A Ordinary Shares.
• The transactions occurred on December 1, 2025, and were executed pursuant to a Rule 10b5-1 plan adopted on August 29, 2025.
• A total of 23,333 Class A Ordinary Shares were sold at a weighted average price of $39.9277 per share, with prices ranging from $39.72 to $40.06.
• An additional 18,242 Class A Ordinary Shares were sold at a weighted average price of $39.9 per share, with prices ranging from $39.60 to $40.03.
• Following these transactions, Marshall Urist beneficially owns 183,334 Class A Ordinary Shares indirectly through Sandy Lamm LLC, 25,640 Class A Ordinary Shares directly, and 19,020 Class A Ordinary Shares indirectly through an IRA.
• Urist also holds limited partnership interests in RPI US Partners 2019, LP, exchangeable into 2,474,120 Class A Ordinary Shares.
• Furthermore, Urist holds 1,356,528 Class E Ordinary Shares of Royalty Pharma Holdings Ltd, some of which are subject to vesting conditions and may convert into Class A Ordinary Shares upon vesting.

Sentiment

Score: 5

Explanation: The filing reports a routine, pre-planned insider sale under a 10b5-1 plan. This type of transaction is generally neutral in sentiment as it's for personal financial planning and not typically indicative of a change in company fundamentals or management's outlook.

Positives

• The sales were conducted under a pre-arranged 10b5-1 plan, indicating planned liquidity management rather than a reactive response to new information.

Negatives

• Insider selling, even if pre-planned, can sometimes be perceived negatively by the market as it reduces an executive's direct equity stake.

Risks

• No specific new risks were identified in this Form 4 filing beyond the general market perception of insider sales.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

Insider transaction reports like Form 4 are routine disclosures in the U.S. financial markets. Sales executed under Rule 10b5-1 plans are common among executives for personal financial planning and liquidity, and are generally viewed as less indicative of management's sentiment about the company's future than unplanned sales.

Stakeholder Impact

• Shareholders may note the reduction in direct and indirect Class A Ordinary Share holdings by a key executive, although the pre-planned nature mitigates concerns.

Key Dates

Recommendation

This Form 4 filing details a routine, pre-planned insider sale under a 10b5-1 plan. Such transactions are typically for personal liquidity or portfolio diversification and do not inherently signal a change in the company's fundamental prospects. The volume of shares sold is not exceptionally large relative to the executive's total potential holdings, thus it does not provide new information that would warrant a change in investment recommendation based solely on this filing.

Keywords

Royalty Pharma, RPRX, Insider Transaction, Form 4, Share Sale, Marshall Urist, 10b5-1 Plan, Executive Compensation